Evidence map›Paper›PMID 38995116›Full record

ArticlePediatric pulmonology2024

Treatment of small as well as large declines in lung function enhances recovery to baseline in people with CF.

Michael S Schechter, Joshua S Ostrenga, Elizabeth A Cromwell, Clement L Ren, Aliza K Fink, D B Sanders, Wayne J Morgan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pediatric pulmonology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Michael S SchechterChildren's Hospital of Richmond at Virginia Commonwealth University, Richmond, Virginia, USA.ORCID 0000-0002-8473-3767
Joshua S OstrengaCystic Fibrosis Foundation, Bethesda, Maryland, USA.
Elizabeth A CromwellCystic Fibrosis Foundation, Bethesda, Maryland, USA.ORCID 0000-0002-5106-0607
Clement L RenChildren's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.ORCID 0000-0003-4431-0644
Aliza K FinkCystic Fibrosis Foundation, Bethesda, Maryland, USA.
D B SandersIndiana University., Indianapolis, Indiana, USA.ORCID 0000-0001-6265-6249
Wayne J MorganUniversity of Arizona, Tucson, Arizona, USA.ORCID 0000-0002-6346-8140

Funding

Cystic Fibrosis Foundation
6 · The paper itself

Abstract

backgroundThe benefit of antibiotic treatment of acute drops in FEV

methodsWe used data from the CF Foundation Patient Registry (CFFPR) from 2016 to 2019 to determine the association between treatment (any IV antibiotics, only oral or newly prescribed inhaled antibiotics, or no antibiotic therapy) following a decline of ≥5% from baseline FEV

resultsOverall, 16,495 PWCF had a decline: 16.5% were treated with IV antibiotics, 25.0% non-IV antibiotics, and 58.5% received no antibiotics. Antibiotic treatment was more likely for those with lower lung function, history of a positive PA culture, older age and larger FEV

conclusionsA large proportion of acute drops in FEV1

Indexed as

Anti-Bacterial AgentsCystic FibrosisAdministration, InhalationAdolescentAdultChildFemaleForced Expiratory VolumeHumansLungMaleRecovery of FunctionRegistriesRespiratory Function TestsYoung AdultAnti-Bacterial Agentsantibioticscystic fibrosislung functionpulmonary exacerbation

Identifiers

PMID38995116
PMCPMC11601011

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.